Abstract： Objective To evaluate the effect of budesonide formoterol combined with tiotropium bromide on stable chronic obstructive pulmonary disease (COPD).Methods Totally 100 patients with stable COPD in Central Hospital of Enshi Autonomous Prefecture firom January to December 2013 were enrolled and randomized into group A (33 cases) receiving budesonide formoterol inhalation powder (12 g/spray, 1 spray/time, 1 time/d), group B (33 cases) receiving tiotropium bromide inhalation powder atomizing agent (18 g/spray, 1 spray/time, 1 time/d), group C (34 cases) receiving budesonide formoterol inhalation powder combined with tiotropium bromide inhalation powder atomizing agent (interval of 30 min between two drugs).Before and 3 months after treatment the lung function indices including forced expiratory volume in one second (FEV1), ratio of FEV1 and forced vital capacity (FVC).FEV1 percentage for predictive value (FEV1％) were measured;the St.George's Respiratory Questionnaire (SGRQ) score was assessed and the adverse reactions were analyzed among three groups.Results No significant differences of FEV1, FEV1/FVC and FEV1％ before treatment were found among three groups [(1.02±0.18) L vs (1.05 ± 0.19) L vs (1.04±0.15) L, (50.1 ±3.5)％ vs (50.2±3.8)％ vs (50.3 ±3.9)％.(43 ±5)％ vs (44 ±6)％ vs (44±6)％] (all P＞0.05).After treatment, the FEV1.FEV1/FVC and FEV1％ in group C were all statistically higher than those in group A and B [(1.35±0.17) L vs (1.21 ±0.16), (1.24 ±0.12)L: (57.8 ±2.7)％ vs (53.1 ±3.2)％, (53.2± 3.0) ％ : (52 ± 6) ％ vs (48 ± 5) ％, (48 ± 6) ％] (all P ＜ 0.05), but no statistical differences were found between group A and B (P ＞ 0.05).There was no significant difference regarding SGRQ score among the three groups before treatment [(53 ± 5) scores vs (53 ± 5) scores vs (53 ± 6) scores] (P ＞ 0.05);after treatment, the SGRQ score in group C was significantly lower than that in group A and B [(46 ± 5) scores vs (50 ± 6), (50 ± 5) scores] (all P ＜ 0.05), while no significant difference was found between group A and B (P ＞ 0.05).The incidence of adverse reactions had no statistical differences among the three groups (P ＞ 0.05).Conclusion Budesonide formoterol combined with tiotropium bromide is safe and effective in treating stable COPD than single application of them, without increasing adverse drug reactions.